[Natalizumab retreatment: effectiveness and long-term safety in multiple sclerosis in the STRATA study]

Ideggyogy Sz. 2014 Jul 30;67(7-8):277-9.
[Article in Hungarian]
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Clinical Trials as Topic
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Multicenter Studies as Topic
  • Multiple Sclerosis / drug therapy*
  • Natalizumab
  • Research Design
  • Sample Size
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • Natalizumab